Medidata Solutions Inc (MDSO), a cloud-based software player in the clinical research segment, is gaining share and seeing accelerated revenue growth and margin improvement as it adds functionality to its core data-capture product, says David H. Windley, Managing Director at Jefferies & Company, Inc.
“[Medidata] has, in the clinical research world, a better mousetrap, and the customer base is recognizing that. Medidata is gaining share, displacing its competitors and seeing its revenue growth accelerate as a result. With that stronger revenue growth, it is also seeing margin improvement, which we think is important,” Windley said.
FOR MORE INFORMATION ABOUT THIS INTERVIEW CLICK HERE.
Medidata is seeing benefits as a cloud-based software company, Windley says, and is also developing more functionality to its core data-capture product, Rave, to aid clinical research operations in managing their activities.
“Medidata benefits from the efficiency of deploying software solutions through the cloud. It is also developing complementary functionality to its core product, Rave, which is a data-capture tool. You could kind of think of it as the EMR for clinical trials. Medidata is trying to surround that with other functionality that helps the research enterprise manage its broad spectrum of activities,” Windley said.
Medidata Solutions (MDSO) Provides Key Clinical-Research SaaS Solutions for Big Pharma
November 01, 2012
Medidata Solutions (NASDAQ:MDSO) Ready to Replace Oracle (NASDAQ:ORCL) in Clinical Trials Cloud Software
October 12, 2017
Medidata Solutions Inc (MDSO) Poised for Pricing Power
May 22, 2015
21st Century Cures Act Likely to Accelerate Demand for Medidata Solutions Inc (MDSO)
November 03, 2015
New Oriental Education & Tech Grp (ADR) (NYSE:EDU) to Sustain Year-on-Year Margin Improvement and Solid Top-Line Growth
September 04, 2013
